NUVALENT INC
Nuvalent, Inc. (NUVL) is a clinical‑stage biotechnology company focused on precision oncology, developing targeted small‑molecule therapies against specific genetic drivers of cancer. With a market capitalisation of about $7.01 billion, the company’s value is largely driven by clinical trial progress, safety and efficacy readouts, regulatory milestones and potential collaborations or licensing deals rather than product revenue. Investors should expect higher volatility common to clinical‑stage biotechs: favourable trial results or partnerships can lift sentiment, while setbacks, delays or disappointing data can lead to sharp declines. Like many peers, Nuvalent may require additional funding as programmes advance, which can dilute existing shareholders. This summary is educational only and not personalised investment advice; prospective investors should assess their risk tolerance, consult multiple information sources (regulatory filings, clinical data and company statements) and consider professional financial guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nuvalent's stock, expecting its value to rise significantly.
Financial Health
Nuvalent Inc is showing strong financial performance with solid cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ABSCI CORP
ABSCI Corporation is a biotechnology company focused on the discovery and development of targeted immune modulators for the treatment of cancer and other diseases.
Baskets Featuring NUVL
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
Develops targeted small‑molecule programmes against specific genetic drivers; scientific progress can attract partners, though trials carry inherent risk.
Catalysts to watch
Upcoming clinical readouts, regulatory milestones and collaboration announcements can move the stock significantly, but outcomes are uncertain.
Funding and partnerships
Partnerships may de‑risk programmes and add resources, while additional financing could dilute shareholders — both materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
